Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Yaxun Jia"'
Publikováno v:
BMC Bioinformatics, Vol 25, Iss 1, Pp 1-28 (2024)
Abstract Background Relation extraction (RE) plays a crucial role in biomedical research as it is essential for uncovering complex semantic relationships between entities in textual data. Given the significance of RE in biomedical informatics and the
Externí odkaz:
https://doaj.org/article/bc1fc73af48342559367ee7c3b12b10f
Publikováno v:
IEEE Access, Vol 12, Pp 134167-134184 (2024)
The identification of Drug-Drug Interactions (DDIs) is crucial for optimizing patient treatment and avoiding adverse reactions. With the rapid growth of biomedical literature, manual screening for DDIs has become impractical. Hence, the demand for au
Externí odkaz:
https://doaj.org/article/6698bf21a7134a8cadc3df5b6779d155
Autor:
Yuan Zhang, Xiang Gao, Jingyan Yi, Xiaolin Sang, Zhihong Dai, Zhiwei Tao, Min Wang, Lanlin Shen, Yaxun Jia, Daqing Xie, Hailing Cheng, Zhiyu Liu, Pixu Liu
Publikováno v:
Cell Death and Disease, Vol 12, Iss 1, Pp 1-15 (2021)
Abstract High levels of Basic Transcription Factor 3 (BTF3) have been associated with prostate cancer. However, the mechanisms underlying the role of BTF3 as an oncogenic transcription factor in prostate tumorigenesis have not been explored. Herein,
Externí odkaz:
https://doaj.org/article/294c0a2da88b424ead105cfe881aca98
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responder
Externí odkaz:
https://doaj.org/article/bed131ecf2a94eb6937f54e1672e3ccb
Autor:
Jingyan Yi, Chongya Liu, Zhiwei Tao, Min Wang, Yaxun Jia, Xiaolin Sang, Lanlin Shen, Yijue Xue, Kui Jiang, Fuwen Luo, Pixu Liu, Hailing Cheng
Publikováno v:
EBioMedicine, Vol 43, Iss , Pp 225-237 (2019)
Background: While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve clinical response. Meanwhile, extending
Externí odkaz:
https://doaj.org/article/f53d36afe16b4bcb8a9eaaa5adf3f8dc
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responder
Autor:
Hailing Cheng, Yijue Xue, Fuwen Luo, Kui Jiang, Pixu Liu, Lanlin Shen, Yaxun Jia, Xiaolin Sang, Chongya Liu, Zhiwei Tao, Min Wang, Jingyan Yi
Publikováno v:
EBioMedicine. 43:225-237
Background While PARP inhibitors and CDK4/6 inhibitors, the two classes of FDA-approved agents, have shown promising clinical benefits, there is an urgent need to develop new therapeutic strategies to improve clinical response. Meanwhile, extending t
Autor:
Pixu Liu, Hailing Cheng, Yaxun Jia, Zhiyu Liu, Lanlin Shen, Xiaolin Sang, Yuan Zhang, Xiang Gao, Min Wang, Jingyan Yi, Daqing Xie, Zhiwei Tao, Zhihong Dai
Publikováno v:
Cell Death and Disease, Vol 12, Iss 1, Pp 1-15 (2021)
Cell Death & Disease
Cell Death & Disease
High levels of Basic Transcription Factor 3 (BTF3) have been associated with prostate cancer. However, the mechanisms underlying the role of BTF3 as an oncogenic transcription factor in prostate tumorigenesis have not been explored. Herein, we report